THE AUTHORS RESPOND
J Manag Care Spec Pharm
.
2021 Aug;27(8):1141.
doi: 10.18553/jmcp.2021.27.8.1141.
Authors
Gregory F Guzauskas
1
,
Ryan N Hansen
1
Affiliation
1
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute Department of Pharmacy, University of Washington, Seattle.
PMID:
34337997
PMCID:
PMC10391291
DOI:
10.18553/jmcp.2021.27.8.1141
No abstract available
Publication types
Letter
Comment
MeSH terms
Cost-Benefit Analysis
Diabetes Mellitus, Type 2*
Glucagon-Like Peptides
Humans
Hypoglycemic Agents*
Substances
Hypoglycemic Agents
semaglutide
Glucagon-Like Peptides